An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Taysha Gene Therapies to Participate in Upcoming April Investor Healthcare Conferences
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Guggenheim Genomic Medicines and Rare Disease Conference on April 1, 2022 at 4:00 pm ET
21st Annual Needham Virtual Healthcare ConferenceApril 11, 2022 at 11:45 am ET
DALLAS--(BUSINESS WIRE)--
Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced its participation in upcoming fireside chats at the Guggenheim Genomic Medicines and Rare Disease Day Conference and the 21st Annual Needham Virtual Healthcare Conference.
Conference Details:
Event:
Guggenheim Genomic Medicines and Rare Disease Day Conference
Date:
April 1, 2022
Time:
4:00 pm ET
Format:
Fireside Chat
Participants:
RA Session II, President, Founder and CEO
Dr. Suyash Prasad, Chief Medical Officer and Head of R&D
Kamran Alam, Chief Financial Officer
Conference Details:
Event:
21st Annual Needham Virtual Healthcare Conference
Date:
April 11, 2022
Time:
11:45 am ET
Format:
Fireside Chat
Participants:
RA Session II, President, Founder and CEO
Dr. Suyash Prasad, Chief Medical Officer and Head of R&D
Kamran Alam, Chief Financial Officer
About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives. More information is available at www.tayshagtx.com.
taysha gene therapies, inc., a gene therapy company, develops adeno-associated virus based gene therapies for the treatment of monogenic diseases of the central nervous system. it primarily develops tsha-101 for the treatment of gm2 gangliosidosis; tsha-118 for the treatment of cln1 disease; tsha-102 for the treatment of rett syndrome; tsha-103 for the treatment of slc6a1 haploinsufficiency disorder; and tsha-104 for the treatment for surfeit locus 1 deficiency. the company also has strategic partnership with the university of texas southwestern medical center to develop and commercialize transformative gene therapy treatments. taysha gene therapies, inc. was founded in 2019 and is based in dallas, texas.
